Latest Breaking News On - Solid tumor oncology - Page 1 : comparemela.com

JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise

A novel radioligand therapy, JNJ-6420, demonstrates potential in treating mCRPCr, delivering sustained responses following only 1-2 doses.

Michaelj morrisMemorial sloan kettering cancer centerDivision of solid tumor oncologySolid tumor oncology

Dr Rosenberg on Efforts to Enhance Urothelial Cancer Treatment

Jonathan E. Rosenberg, MD, discusses ongoing and planned research efforts to enhance the frontline and beyond urothelial cancer treatment landscape.

Ennow ercklentz jrJonathane rosenbergGenitourinary oncology serviceMemorial sloan kettering cancer centerDivision of solid tumor oncologySolid tumor oncology

Dr Rosenberg on Toxicity Management With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

Jonathan E. Rosenberg, MD, discusses toxicity management when administering enfortumab vedotin plus pembrolizumab in urothelial cancer.

Jonathane rosenbergEnnow ercklentz jrGenitourinary oncology serviceMemorial sloan kettering cancer centerDivision of solid tumor oncologySolid tumor oncology

ADCs and Immunotherapy Broaden the Bladder Cancer Treatment Paradigm

Jonathan E. Rosenberg, MD, discusses how recent FDA approvals have revolutionized the treatment paradigm for locally advanced or metastatic bladder cancer.

New yorkUnited statesJonathane rosenbergEnnow ercklentz jrMemorial sloan kettering cancer centerGenitourinary oncology serviceDivision of solid tumor oncologySolid tumor oncologyEnfortumab vedotinUrothelial cancerOcally advanced or metastatic bladder cancer

APCCC 2024: Ideal Monitoring of Patients with mHSPC – What Is Recommended in Daily Clinical Practice?

APCCC 2024: Ideal Monitoring of Patients with mHSPC – What Is Recommended in Daily Clinical Practice?
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMemorial sloan kettering cancer centerMichael morrisSociety of urologic oncologyProstate cancer working groupUniversity of torontoInternational multicenter studyDivision of solid tumor oncologyProstate cancer consensus conferenceResponse evaluation usingMetastatic castration resistant prostate cancerMedical oncologistClinical directorGenitourinary medical oncology serviceProstate cancer section head